HK1249428A1 - 預防或治療缺血/再灌注損傷之後無複流的方法 - Google Patents

預防或治療缺血/再灌注損傷之後無複流的方法

Info

Publication number
HK1249428A1
HK1249428A1 HK18109055.3A HK18109055A HK1249428A1 HK 1249428 A1 HK1249428 A1 HK 1249428A1 HK 18109055 A HK18109055 A HK 18109055A HK 1249428 A1 HK1249428 A1 HK 1249428A1
Authority
HK
Hong Kong
Prior art keywords
prevention
treatment
methods
reperfusion injury
following ischemia
Prior art date
Application number
HK18109055.3A
Other languages
English (en)
Inventor
肯尼斯‧博羅
D‧特拉維斯‧威爾遜
羅伯特‧A‧科魯納
莎倫‧黒勒
Original Assignee
康得生物醫療技術公司
好撒瑪利亞人研究與教育機構
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 康得生物醫療技術公司, 好撒瑪利亞人研究與教育機構 filed Critical 康得生物醫療技術公司
Publication of HK1249428A1 publication Critical patent/HK1249428A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
HK18109055.3A 2010-07-09 2018-07-12 預防或治療缺血/再灌注損傷之後無複流的方法 HK1249428A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36312910P 2010-07-09 2010-07-09
US36313310P 2010-07-09 2010-07-09
US41265510P 2010-11-11 2010-11-11

Publications (1)

Publication Number Publication Date
HK1249428A1 true HK1249428A1 (zh) 2018-11-02

Family

ID=45441572

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109055.3A HK1249428A1 (zh) 2010-07-09 2018-07-12 預防或治療缺血/再灌注損傷之後無複流的方法

Country Status (7)

Country Link
US (2) US9345738B2 (zh)
EP (3) EP2590664B1 (zh)
JP (5) JP6319738B2 (zh)
CN (4) CN107569675A (zh)
CA (1) CA2804404C (zh)
HK (1) HK1249428A1 (zh)
WO (1) WO2012006569A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858550A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
AU2013222423A1 (en) * 2012-02-22 2014-09-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP3406257B1 (en) * 2012-03-30 2020-04-22 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
WO2014185952A1 (en) * 2013-05-14 2014-11-20 Stealth Peptides International, Inc. Methods for the prevention or treatment of left ventricle remodeling
WO2014210056A1 (en) * 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
WO2018187400A1 (en) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
IL300697B2 (en) * 2017-12-15 2024-03-01 Stealth Biotherapeutics Inc Mitochondria-targeted peptides
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CN113271874B (zh) * 2018-09-21 2024-07-23 康福乐医疗公司 用于评估微血管功能障碍的设备
IL284006B1 (en) * 2018-12-18 2024-08-01 Stealth Biotherapeutics Corp Mitochondria-targeted peptides
WO2020131283A1 (en) * 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases
WO2020189593A1 (ja) 2019-03-20 2020-09-24 三菱ケミカル株式会社 重合体、分離剤、重合体の製造方法、化合物の分離方法及び化合物の製造方法
RU2711414C1 (ru) * 2019-03-27 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Способ прогнозирования асимптомного повреждения вещества головного мозга при ангиореконструктивных операциях на сонных артериях
CN114466656A (zh) 2019-07-24 2022-05-10 康德生物医疗有限公司 在治疗神经变性病症中的模拟肽化合物(r)-2-氨基-n-((s)-1-(((s)-5-氨基-1-(3-苄基-1,2,4-噁二唑-5-基)戊基)氨基)-3-(4-羟基-2,6-二甲苯基)-1-氧代丙-2-基)-5-胍基戊酰胺
JP7533970B2 (ja) * 2022-01-31 2024-08-14 株式会社ニューギン 遊技機
JP7478453B2 (ja) * 2022-01-31 2024-05-07 株式会社ニューギン 遊技機

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5182106A (en) 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
JPH05301868A (ja) 1992-04-23 1993-11-16 Mitsui Toatsu Chem Inc 虚血性心疾患治療剤
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2004013173A1 (ja) 2002-08-01 2004-02-12 Yamanouchi Pharmaceutical Co., Ltd. 新規なカリウム依存的ナトリウム−カルシウム交換体
HUE027110T2 (en) * 2003-02-04 2016-08-29 Cornell Res Foundation Inc Use of an aromatic cationic peptide
RU2376028C2 (ru) 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
EP1931369B1 (en) * 2005-09-16 2016-08-17 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing CD36 expression
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHODS OF REALIZING AORTO-CORONARY BRIDGE
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Also Published As

Publication number Publication date
CN103249423A (zh) 2013-08-14
CA2804404A1 (en) 2012-01-12
JP2022012924A (ja) 2022-01-17
US10322159B2 (en) 2019-06-18
JP2013531682A (ja) 2013-08-08
EP2590664A1 (en) 2013-05-15
CN106620645A (zh) 2017-05-10
WO2012006569A1 (en) 2012-01-12
US20170087204A1 (en) 2017-03-30
EP3539554A1 (en) 2019-09-18
JP2020114880A (ja) 2020-07-30
EP4285994A3 (en) 2024-01-17
EP2590664A4 (en) 2014-01-15
JP2016172781A (ja) 2016-09-29
US20130196921A1 (en) 2013-08-01
JP6319738B2 (ja) 2018-05-09
JP2019052188A (ja) 2019-04-04
CN105879008A (zh) 2016-08-24
EP2590664B1 (en) 2019-03-27
EP4285994A2 (en) 2023-12-06
CA2804404C (en) 2020-10-20
US9345738B2 (en) 2016-05-24
CN107569675A (zh) 2018-01-12

Similar Documents

Publication Publication Date Title
HK1249428A1 (zh) 預防或治療缺血/再灌注損傷之後無複流的方法
IL262611A (en) Treatment for lipodystrophy
HUE037592T2 (hu) Eljárások cerebrális ischemia megelõzésére és kezelésére
EP2875824A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF CACHEXIA
HK1210085A1 (zh) 用於水淨化的方法和裝置
EP2861627A4 (en) PROCESS FOR INCREASING THE EXTRACTIBLE RUBBER CONTENT OF NON-HEVEA PLANT MATERIAL
HRP20181950T1 (hr) Samidorfan (alks 33) u kombinaciji s buprenorfinom za liječenje depresivnih poremećaja
HK1209424A1 (zh) 用於治療再灌注損傷的氧雜二環庚烷和氧雜二環庚烯
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
HK1199616A1 (zh) 惡病質治療
AP2015008338A0 (en) Compounds for the treatment and prevention of retroviral infections
EP2878302A4 (en) COMPOSITION FOR PREVENTING OR TREATING OSTEOARTHRITIS
EP2536436A4 (en) ANTIMIR-451 FOR THE TREATMENT OF POLYCYTHEMICS
HK1201181A1 (zh) 用於治療和預防病毒感染的新型環孢菌素衍生物
EP2744502A4 (en) METHODS USEFUL IN PREVENTING HYPOXIC INJURY
EP2616485A4 (en) STEPPED DEVELOPED PEPTIDE FOR THE TREATMENT OF BRAIN INJURIES
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
EP2675448A4 (en) METHOD FOR TREATING ISCHEMIA / REPERFUSION INJURIES
PL2872131T3 (pl) Oleaceina do leczenia lub zapobiegania chorobom będących następstwem blaszki miażdżycowej
EP2588146A4 (en) TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS BY L-METHYLFOLATE
GB201219696D0 (en) Agents for the prevention and/or treatment of central nervous system damamge
GB201221362D0 (en) Inhibiting the decomposition of acidulants
GB201221197D0 (en) Inhibiting the decomposition of acidulants
HUP1200221A2 (en) Sludge treatment
PL120341U1 (pl) Zespól do powierzchniowej obróbki wlewków aluminium